Chymase is predominantly involved in the intramural production of angiotensin II (Ang II) in the human heart, arteries and lungs, whereas the angiotensin converting enzyme (ACE) is responsible for genesis of the vasoactive peptide in the circulation (Fleming, 2006) . Moreover, chymase is involved in extracellular matrix remodeling (Kielty et al., 1993; Kofford et al., 1997) as well as in the degradation of apolipoprotein E (Lee et al., 2002) , thrombin and fibrin (Tchougounova et al., 2003) . The interstitial Ang II-forming characteristic of chymase is explained by the fact that this enzyme is interfered within the circulation by blood-borne endogenous protease inhibitors, such as α 1 trypsin and α 1 macroglobulin (Lindstedt et al., 2001 ). Intimal-located remnant granules derived from degranulated mast cells, however, release an heparin-bonded chymase which reduces the interfering properties of these high molecular-weight protease inhibitors on chymasic activity (Lindstedt et al., 2001; Miyazaki et al., 2006) .
There are two known isoforms of chymase namely, α -and β -chymases. The former is mainly found in humans, monkeys, sheep and hamsters whereas the later is also found in rats and mice (Doggrell and Wanstall, 2004) . In mice, chymases are members of the murine mast cell protease family (mMCPs). While mMCP-1, 2 and 4 are β -chymases, mMCP-5 is considered as α -chymase based on structural comparison or phylogenetical analysis (Gallwitz and Hellman, 2006) . Interestingly, the only human gene responsible for the expression of the human α -chymase shares most of its functional similarity with the mMCP-4, a β -chymase (Andersson et al., 2008) .
JPET #142992 9 NY, USA). The homogenates were centrifuged at 14,000 g for 20 min at 4°C. The pellets were discarded and the supernatant was used for the assay. The substrate-specific enzymatic activity was measured at 37°C in a 0.2 ml reaction mixture comprising 100 mM of fluorogenic peptide substrate, Suc-Leu-Leu-Val-Tyr-MCA, in 100 mM potassium phosphate buffer, pH 8. The amount of 7-amino-4-methylcoumarin (MCA) liberated from the substrate was determined fluorometrically (λ ex 370 and λ em 460 nm) with a fluorescence spectrophotometer (Molecular Device, Sunnyvale, CA, USA).
Hemodynamic Studies
All mice were induced and maintained under ketamine/xylazine (87/13 mg/kg; i.m.) anesthesia throughout hemodynamic experiments. The left jugular vein and the right carotid artery were cannulated using a polyethylene-10 catheter, the former for iv. injection and the later for blood pressure monitoring or blood sampling. Mean arterial blood pressure (MAP) and heart rate (HR)
were monitored using a Blood Pressure Analyzer-200A (Micro-Med, Tustin, California, USA).
Basal MAP was averaged at 60.5 ± 1.7 mmHg and HR at 163.8 ± 9.8 bpm in all anesthetized mice tested in the present study (n=130). Anesthetized animals were allowed to stabilize from the surgical procedure for 20 min prior to pharmacological interventions and data were then recorded for 15 minutes following the intravenous administration of Big ET-1 (1-38), ET-1 (1-31) or ET-1 in each experiment. ED 50 s were expressed as the dose (nmol/kg) of agonist necessary to induce 50% of the maximal pressor response and calculated using a fit curve analysis.
In other series of experiments, BQ-123 (ET A antagonist), BQ-788 (ET B antagonist) and phosphoramidon (ECE/NEP inhibitor) (Fukuroda et al., 1990) were administered intravenously 5 minutes before Big ET-1 or its derivatives. Thiorphan (NEP inhibitor) (Roques et al., 1980) and This article has not been copyedited and formatted. The final version may differ from this version. Incubation times for antagonists (5 minutes) and inhibitors (15-20 minutes) were selected in accordance to previous reports (Honoré et al., 2002; Fecteau et al., 2005) . Furthermore, vehicles used to dissolve both antagonists and inhibitors were systematically administered before each agonist for control purpose and were without effect on all parameters studied in each series of experiments.
Blood Sample Preparation
In separate groups of mice pretreated with vehicle, chymostatin or Suc-Val-Pro-Phe P (OPh) 2 , blood samples were collected 1 min after iv. injection of Big ET-1 for the measurement of immunoreactive ET-1 (1-31) or ET-1. Blood samples (100 µl) were collected in trisodium citrate (3.5%) in a 9:1 ratio (vol/vol), immediately centrifuged for 1 minute at 19 800 g for blood content separation and 50 µl of plasma samples were stored at -80 °C until assayed by HPLC.
High performance liquid chromatography (HPLC) separation and RIA and EIA Analysis
A reversed-phase HPLC analysis was performed using a Zorbax 300SB-C18 column (Agilent, Mississauga, ON, Canada). Samples were eluted with a 35-minute linear gradient of acetonitrile (from 28% to 40%) in 0.1% TFA at a flow rate of 1 ml/min using a Waters model determination of ET-1 and ET-1 (1-31) levels, respectively. For calibration purposes, synthetic ET-1, ET-1 (1-31) or Big ET-1 were run separately or conjointly and positions of the eluted standards were determined by ultraviolet absorbance (214 nm) and confirmed by RIA and EIA.
Immunoreactive (IR)-ET was measured by a RIA kit (RPA 555, GE Healthcare BioSciences Corp., Piscataway, NJ, USA) as previously reported (Gratton et al., 1997) . IR-ET-1 (1-31) was monitored with an EIA kit (Pheonix Bio-tech inc., Mississauga, ON, Canada). Plasma peptide concentrations are shown uncorrected for extraction recovery.
Drugs and Solutions
ET-1, ET-1 (1-31), Big ET-1 and phosphoramidon (N-(α-Rhamno-pyranosyl-oxy-hydroxyphosphinyl)-Leu-Trp disodium salt) were purchased from Peptide International (Louisville, Figure 4A ). Thiorphan was not tested at higher doses because of cardiotoxic effects. Figure 4B , in contrast, shows that the pressor response to ET-1 (1-31) was abolished by phosphoramidon and thiorphan but unaltered by the ECE-selective inhibitor CGS 35066.
As a final control none of the three above mentioned inhibitors interfered with the pressor response to ET-1 ( Figure 4B ).
Big ET-1 induces chymase-inhibitor-sensitive pressor response
The pressor response to Big ET-1, ET-1 (1-31) and ET-1 were also tested in mice pretreated with chymostastin (20 mg/kg). The non specific chymase inhibitor reduced the pressor response to Big ET-1 (1 nmol/kg) without affecting those of ET-1 (1-31) (1 nmol/kg) and ET-1 (0.5 nmol/kg) ( Figure 5A ).
In another series of experiments, Suc-Val-Pro-Phe P (OPh) 2 markedly reduced to pressor response induced by Big ET-1 ( Figure 5A ). Moreover, the specific chymase inhibitor did not alter those afforded by ET-1 (1-31) or ET-1 ( Figure 5B ). Moreover, dual ECE/Chymase inhibition following co-administration of CGS 35066 and Suc-Val-Pro-Phe P (OPh) 2 further inhibited the maximal increase of MAP observed with systemically administered Big ET-1 ( Figure 5A ). Finally, figure 5C shows that the administration of Suc-Val-Pro-Phe P (OPh) 2 induces a long lasting inhibition of the pressor response to Big ET-1 (1 nmol/kg).
Chymase-dependent conversion of Big ET-1 to ET-1 in vivo
Plasma levels of both ET-1 (1-31) and ET-1 following systemic administration of Big ET-1 were measured by EIA and RIA, respectively, in mice pretreated with vehicle or chymase inhibitors. Figure 6A shows that the reverse HPLC gradient used was able to effectively separate high This article has not been copyedited and formatted. The final version may differ from this version. amount of synthetic Big ET-1 from ET-1 (1-31) and ET-1 in extracted plasma via ultraviolet absorbance detection. Moreover, when Big ET-1 was systemically administered in anesthetized mice, the HPLC approach combined with immunodetection confirmed the separation of ET-1 (1-31) and ET-1 produced de novo ( Figure 6B ). Basal levels of both ET-1 (1-31) and ET-1 were under detection threshold levels due the limited systemic blood volumes than can be acutely drawn from mice without inducing hypovolemia.
Furthermore, the nonspecific chymase inhibitor, chymostatin, abolished the increase in plasma levels of ET-1 (1-31) following administration of Big ET-1 ( Figure 7A ). In addition, chymostatin did not interfere with the increased plasma levels of ET-1 (1-31) following systemic administration of the same peptide ( Figure 7B ).
Finally, Suc-Val-Pro-Phe P (OPh) 2 administered prior to Big ET-1, abolished the increases in plasma levels of immunoreactive ET-1 (1-31) ( Figure 7C ) and ET-1 ( Figure 7D ).
This article has not been copyedited and formatted. The final version may differ from this version. 
DISCUSSION
The two main results of the present study are firstly that chymase is significantly involved in the pressor response to Big ET-1 and that ET-1 (1-31) requires the activity of the neutral endopeptidase to increase blood pressure in the mouse model. Furthermore, our data suggest that chymase is also pivotal in the increased plasma levels of ET-1 (1-31) and ET-1 following systemically administered of Big ET-1.
Unlike the ECE or the NEP, chymase is not a membrane bound serine protease albeit the activity of the later enzyme is limited in the circulation by blood borne endogenous inhibitors (Lindstedt et al., 2001) . Interestingly, in the present study we were able to detect chymase-like activity in the supernatant of cardiac, pulmonary and aorta homogenates of the mouse.
Worthy of notice chymase is also located in the adventia and media of human coronary arteries (Borland et al., 2005) ; a significant contribution of that particular vasculature should therefore be also taken into account in the overall chymase activity detected, in the present study in the whole heart homogenates of the mouse. Finally, marked increase in cardiac mMCP-4 and mMCP-5 mRNA levels has been shown in a mouse model of heart failure (Kitaura-Inenaga et al.,
2003), thus confirming the present results as far as the presence of both chymase isoforms are concerned in cardiac homogenates.
We suggest that chymostatin is more efficient than Suc-Val-Pro-Phe Finally the dual inhibition of the ECE and chymase promotes an additional reduction in the pressor response to Big ET-1. Thus, we have shown that the pressor responses to Big ET-1 and ET-1 (1-31) are predominantly amenable by combined chymase/ECE for the former and fully by NEP processes for the later peptide.
In the present in vivo model, ET-1 (1-31) requires the obligatory contribution of NEP to induce its pressor response. Albeit not demonstrated in the present study, we suggest that first pass of intravascular administered ET-1 (1-31) in the lungs, which is a NEP rich organ (Baraniuk et al., 1995) , may be involved in this process. In support of our hypothesis, high mRNA levels of NEP 24.11 were measured in murine pulmonary and, interestingly, in aorta derived homogenates.
Indeed, the mRNA monitoring and MCA-studies presented here point out to the presence of marked chymase and NEP activity in the aorta thus providing evidence towards a contribution of this alternate pathway in the processing of Big ET-1 in the conductance vessel as also previously shown by Watts et al. (2007) in isolated rat aortic rings. We also suggest that large conductance vessels such as the aorta might be the main targets for the inhibition of chymase-dependent interstitial conversion of Big ET-1 to ET-1.
This article has not been copyedited and formatted. The final version may differ from this version. We also show that both Suc-Val-Pro-Phe P (OPh) 2 and chymostatin abolished the increases in ET-1
(1-31) plasma levels afforded by systemic administration of Big ET-1. In addition, specific inhibition of chymase markedly blunted the increase plasma levels of ET-1 following administration of the 38 amino acid precursor. Our data also show that chymase had no effect on ET-1 (1-31) plasma levels following systemic administration of the same peptide. We therefore demonstrate for the first time that chymase is the enzyme predominantly involved in the processing of intravascular administered Big ET-1 to ET-1 in the mouse model.
It is worthy of notice that we did not assess the effect of the ECE on the increased ET-1 plasma levels following systemic administration of Big ET-1 in the mouse. Firstly, specific chymase inhibition virtually abolished the increased plasma levels of both ET-1 (1-31) and ET-1, in the present study. Furthermore, Okumura et al. had previously shown that the NEP/ECE inhibitor, phosphoramidon (10 mg/kg) does not alter the increase in ET-1 plasma levels following systemic administration of Big ET-1 in the mouse model (Okumura et al., 1993) , unlike what we have previously reported in the rabbit (Gratton et al., 1997) . This discrepancy points out to interspecies variations and also supports the concept that chymase may play a more important role in the systemic conversion of Big ET-1 than the ECE in the mouse model.
It is, on the other hand, also of importance to point out that the increased levels of ET peptides following administration of the precursor, should be considered as a spill over (i.e.
representing a fraction) of interstitially pre-formed ET-1 (1-31) and ET-1, thus explaining why chymase inhibition abrogates the increased plasma levels of both peptide while only reducing the pressor responses following administration of Big ET-1.
Based on the above considerations, we also suggest the specificity of ECE inhibitors in the cardiovascular system must be assessed pharmacologically as well as biochemically by In conclusion, we suggest that interfering specifically with the ECE pathway with selective inhibitors, would leave unaltered the production of ET-1 (1-31) and the subsequent NEP dependant production of ET-1. Whether the chymase/NEP pathway constitutes a therapeutically valid target towards the endothelin system in vascular diseases will require, however, the full assessment of this paradigm with orally-available chymase inhibitors. 
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